ly3361237
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 26, 2018 (NCT03695198)
Timeline
Indications
Mechanism of action
- BTLAINHIBITOR
BTLA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05781451 | Phase 2 | Oct 1, 2023 | Stanford University |
| NCT05123586 | Phase 2 | Dec 15, 2021 | Eli Lilly |
| NCT04975295 | Phase 1 | Jul 27, 2021 | Eli Lilly |
| NCT03933943 | Phase 1 | May 21, 2019 | Eli Lilly |
| NCT03695198 | Phase 1 | Oct 26, 2018 | Eli Lilly |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 4 | 2 | 2018 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1